Blueprint Medicines announces updated NAVIGATOR trial results
Blueprint Medicines announced updated data for the registration-enabling NAVIGATOR clinical trial of avapritinib. The data showed that avapritinib was highly active across all lines of therapy for patients with PDGFRα D842V-driven GIST and in second-, third- and fourth-line for other GIST patients. November 15, 2018